Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Avanos Medical, Inc.NYSE: AVNS
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock broadly unchanged from a year ago
Common stock stood at $500K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 500K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +0.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 500K | +0.0% |
| FY2024 | 2024-12-31 | 500K | +0.0% |
| FY2023 | 2023-12-31 | 500K | +0.0% |
| FY2022 | 2022-12-31 | 500K | +0.0% |
| FY2021 | 2021-12-31 | 500K | — |
Common Stock vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's Mar 2026 common stock of $500K is the 3rd highest of the 11 companies compared; the peer median is $305.5K.
- Its year-over-year change of +0.0% is the 8th highest of 11, against a peer median of +1.6%.
- Common stock amounts to 0.0% of total assets for AVNS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1M | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $899K | +0.8% | +32.2% | 0.1% | |
| Mar 2026 | $500K | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $408K | +2.8% | +71.6% | 0.1% | |
| Apr 2026 | $400K | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $311K | +3.7% | +10.0% | 0.0% | |
| Mar 2026 | $300K | +7.1% | +6.1% | 0.3% | |
| Mar 2026 | $129K | +0.8% | -1.5% | 0.0% | |
| Mar 2026 | $84K | +2.4% | +2.1% | 0.0% | |
CBLLCeriBell, Inc. | Mar 2026 | $38K | +5.6% | +96.6% | 0.0% |
| Mar 2026 | $5K | +0.0% | +26.0% | 0.0% | |
| Peer median (excluding AVNS) | $305.5K | +1.6% | +8.1% | 0.0% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 118.5M | 127.7M | 87.7M | 107.7M | 89.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 131.2M | 167.9M | 142.8M | 132.8M | 103.8M |
| Inventory | 159.3M | 132.3M | 163.2M | 138.8M | 148M |
| Other Current Assets | 0 | 196.2M | 93.3M | 14.1M | 13.8M |
| Total Current Assets | 427.6M | 624.1M | 487M | 393.4M | 355.4M |
| Property, Plant & Equipment (Net) | 206.7M | 146.1M | 144M | 144.8M | 141M |
| Goodwill | 801.6M | 760.3M | 796.1M | 455.6M | 394.9M |
| Intangible Assets | 141.2M | 234.2M | 239.5M | 112.3M | 117.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 10M | 4.6M | 6.5M | 24.9M | 33.1M |
| Other Non-current Assets | 16.5M | 17.6M | 19.3M | 23.2M | 31.5M |
| Total Non-current Assets | 1.18B | 1.16B | 1.21B | 760.8M | 718.3M |
| Total Assets | 1.6B | 1.79B | 1.69B | 1.15B | 1.07B |
| Account Payables | 56.4M | 67.9M | 56.3M | 54.3M | 55.5M |
| Short-term Debt | 14.7M | 6.2M | 8.6M | 9.4M | 10.2M |
| Tax Payables | 3M | 21.2M | 16.7M | 18M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 35.8M | 7.1M | 108.7M | 73.3M | 0 |
| Total Current Liabilities | 139.2M | 191M | 234.6M | 165.9M | 165.2M |
| Long-term Debt | 130M | 226.3M | 159.4M | 125.3M | 90.3M |
| Deferred Tax Liabilities | 11.9M | 25.4M | 23.8M | 5.5M | 6.1M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 9.1M | 20.5M | 10M | 4.4M | 13.5M |
| Total Non-current Liabilities | 193.8M | 304.7M | 221.5M | 159.8M | 130.3M |
| Total Liabilities | 333M | 495.7M | 456.1M | 325.7M | 295.5M |
| Common Stock | 500K | 500K | 500K | 500K | 500K |
| Retained Earnings | (303.6M) | (253.1M) | (314.9M) | (707M) | (779.9M) |
| Accumulated OCI | (33.8M) | (35.8M) | (27M) | (44.6M) | (32M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.27B | 1.29B | 1.24B | 828.5M | 778.2M |
| Total Debt | 187.5M | 277M | 209.1M | 170.2M | 129.1M |
| Net Debt | 69M | 149.3M | 121.4M | 62.5M | 39.3M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.